Navigation Links
Forest Laboratories, Inc. and Daiichi Sankyo, Inc. Announce the Termination of the AZOR Co-Promotion Agreement

NEW YORK and PARSIPPANY, N.J., May 12 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX), a U.S.-based pharmaceutical company, and Daiichi Sankyo, Inc. today announced that they have terminated their co-promotion agreement for AZOR(TM)* (amlodipine and olmesartan medoxomil), Daiichi Sankyo's fixed-dose combination of two antihypertensives, the calcium channel blocker amlodipine besylate and the angiotensin receptor blocker olmesartan medoxomil. Forest will record a one-time charge of $44.1 million which is composed of a one-time payment to Daiichi Sankyo of $26.6 million related to the termination and $17.5 million related to the unamortized portion of the initial upfront payment.

(Logo: )

The AZOR agreement is the second co-promotion agreement for the two companies. A previous agreement signed in 2002 by Forest to co-promote Benicar(R) (olmesartan medoxomil) and Benicar HCT(R) (olmesartan medoxomil-hydrochlorothiazide) is currently still in force. That agreement specified a co-promotion period, which has been extended to end on May 31, 2008, and a residual period where Forest will continue to receive income from Benicar(R) and Benicar HCT(R) profits, which doesn't expire until March 31, 2014.

Forest has determined that the resources it has allocated to the AZOR co-promotion will be better utilized in providing additional support for Forest's currently marketed products.

Beginning July 1, 2008, Daiichi Sankyo will take sole responsibility for the promotion of AZOR. The company has both expanded its cardiovascular sales capability in recent years and is adding additional capacity in preparation of the potential launch of its investigational anti-platelet agent.

Howard Solomon, Chairman and CEO of Forest, commented: "We have enjoyed a very fruitful partnership with Daiichi Sankyo since our initial collaboration of Benicar which began in 2002. Our decision to reallocate resources to our currently marketed products causes us to forego the opportunity to continue to participate in the promotion of Daiichi Sankyo's excellent product AZOR."

Solomon continued, "However, Daiichi Sankyo and Forest's partnership will continue for another six years during which Forest will have a residual participation in Benicar and Benicar HCT profits, but will not be actively promoting those products. The result of terminating Forest's active promotion of both Benicar and AZOR will make available to Forest the equivalent of an additional 500-person sales force which Forest requires for the support of its proprietary products. We greatly admire Daiichi Sankyo, and we have both benefited from its creative product development, skillful marketing, and the highest standards of ethical partnership."

Daiichi Sankyo President and CEO Joseph P. Pieroni said, "Our first co-promotion agreement with Forest provided us with important additional resources to build our franchise of Benicar and Benicar HCT into significant products in the antihypertensive market while we built our own sales force. Our second co-promotion collaboration for AZOR allowed us to quickly and comprehensively educate the medical community about this new combination antihypertensive. Now we can take over full responsibility for the continued success of these brands."

AZOR was approved by the US Food and Drug Administration September 26, 2007. Forest will continue to co-promote AZOR until June 30, 2008. Health care providers with questions regarding AZOR or any Daiichi Sankyo product should call Daiichi Sankyo at 877 4DSPROD (437-7763).

About Forest Laboratories and Its Products

Forest Laboratories is a U.S.-based pharmaceutical company dedicated to identifying, developing, and delivering products that make a positive difference in people's lives. Forest Laboratories' growing product line includes Lexapro(R) (escitalopram oxalate), an SSRI indicated for adults for the initial and maintenance treatment of major depressive disorder and generalized anxiety disorder; Namenda(R) (memantine HCl), an N-methyl-D-aspartate (NMDA)-receptor antagonist indicated for the treatment of moderate to severe Alzheimer's disease; Campral(R)** (acamprosate calcium), indicated in combination with psychosocial support for the maintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at treatment initiation, and Bystolic(R) (nebivolol), a beta-adrenergic receptor blocking agent indicated for the treatment of hypertension.

About Daiichi Sankyo, Inc.

Daiichi Sankyo, Inc., headquartered in Parsippany, New Jersey, is the U.S. subsidiary of Daiichi Sankyo Co., Ltd., one of Japan's leading pharmaceutical companies and a global leader in pharmaceutical innovation whose roots date back to 1899. The company is dedicated to the discovery, development and commercialization of innovative medicines that improve the lives of patients throughout the world. The primary focus of Daiichi Sankyo's research and development is cardiovascular disease, including therapies for dyslipidemia, hypertension, diabetes, and acute coronary syndrome. The company is also pursuing the discovery of new medicines in the areas of glucose metabolic disorders, infectious diseases, cancer, bone and joint diseases, and immune disorders. For more information, visit

* AZOR is a trademark of Daiichi Sankyo, Inc.

**Campral is a registered trademark of Merck Sante s.a.s., a subsidiary of

Merck KGaA, Darmstadt, Germany.

Except for the historical information contained herein, this release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertainties, including the difficulty of predicting FDA approvals, the acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, the timely development and launch of new products, and the risk factors listed from time to time in the Forest Laboratories' Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and any subsequent SEC filings.

SOURCE Forest Laboratories, Inc.; Daiichi Sankyo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Forest Laboratories, Inc. Announces Amendment to Bystolic(TM) (nebivolol) Agreement
2. Forest Laboratories, Inc. Announces Positive Results of Memantine Study of Once-Daily Formulation
3. Forest Laboratories, Inc. and Merz Pharma GmbH & Co. KgaA File Additional Lawsuit Against Several Companies for Patent Infringement
4. Forest and Cypress Announce Submission of New Drug Application for Milnacipran for the Treatment of Fibromyalgia Syndrome
5. BioSpace Launches 3rd Edition of BioForest(TM) Bioscience Marketing Campaign
6. Drugs from Johnson & Johnson/Basilea and Forest Are the Most Promising Antibiotics in the Community-Acquired Pneumonia Pipeline
7. Nanotube forests grown on silicon chips for future computers, electronics
8. Forest Laboratories Lexapro and Generics-Dominated Fluoxetine Lead First-Line Therapy in the Treatment for Major Depression
9. Microbia and Forest Laboratories Announce Linaclotide Co-Development and Co-Marketing Collaboration
10. Forest Laboratories Announces Federal Appeals Court Upholds Lexapro(R) Patent Decision
11. Clontech Laboratories, Inc. Releases the ProteoTuner(TM) Systems
Post Your Comments:
(Date:10/8/2015)... , Oct. 8, 2015  ATCC, the premier global ... it has been selected by The Michael J. Fox ... lines to academic, pharmaceutical, and biotechnology organizations committed to ... the United States , and more than ... the United States , and more than ...
(Date:10/8/2015)... Maryland , October 8, 2015 ... .   --> Goldman Small ... in the small cap and microcap sectors, announced ... research report on PharmaCyte Biotech, Inc. (OTCQB - ... focused on developing and preparing treatments for cancer ...
(Date:10/8/2015)... 8, 2015  Today, DuPont and Caribou Biosciences, ... editing, jointly announced a strategic alliance. As part ... respective patent portfolios, with DuPont receiving exclusive intellectual ... row crops, and non-exclusive rights in other agricultural ... --> --> In addition, the ...
(Date:10/8/2015)... Oct. 8, 2015  Today the Wyss Institute for ... of its start-up company Opsonix Inc. The ... Harvard,s Office of Technology Development (OTD) and Opsonix ... therapy for clinical use. --> ... a million people every year in the U.S. — ...
Breaking Biology Technology:
... Researchers at Delft University of Technology and Oxford University announce ... developing fast and cheap genetic analysis. In the journal ... method that combines man-made and biological materials to result in ... measure and analyze single DNA molecules. Biological , ...
... a new measurement-based approach to environmental noise monitoring and ... Group, QinetiQ and Hoare Lea Acoustics, and with support ... Distributed Remote Environmental Array & Monitoring System). This ... (Micro Electro Mechanical Systems) microphones to provide a means ...
... was first isolated in 2004 with the help of ... to discover its potential applications. A single layer of ... biosensors to flexible displays, graphene is strong, light, transparent, ... can we do with this new material? As researchers ...
Cached Biology Technology:
(Date:10/7/2015)... October 8, 2015 --> ... Fingerprint Cards (FPC) during third quarter 2015 amounted to around ... around 860 MSEK that was communicated 20 August 2015. ... strengthened delivery capacity and a continued growing demand for the ... estimated to be higher than during the third quarter. The ...
(Date:10/5/2015)... -- ) releases the ... NXTD ), a biometric authentication company focused on ... ) releases the following market and company ... biometric authentication company focused on the growing mobile commerce ... ) releases the following market and company ...
(Date:9/30/2015)... 30, 2015  The U.S. Court of Appeals for ... ruling in favor of Crossmatch ™, affirming the ... company Suprema and its U.S. partner Mentalix violated Section ... provision that declares it unlawful to engage in "unfair ... of Crossmatch,s patents, the 5,900,993 patent and the 7,203,344 ...
Breaking Biology News(10 mins):
... is available in Spanish . In most ... in monogenic diabetes, where the causes are mutations in just a ... or patients with monogenic diabetes do not present alterations in any ... possible causes, and so new candidate genes have had to be ...
... appeared as being in perpetual conflict, but a new study ... at major research universities see religion and science as requiring ... meaning of life, ways of understanding reality, origins of Earth ... and science as being at odds and even in irreconcilable ...
... is available in German . Jean-Baptiste ... of hand his belief that acquired traits can be passed ... Lamarck,s theory of transformation went onto the ash heap of ... the environment can after all leave traces in the genomes ...
Cached Biology News:
... 20 Plasma Immunodepletion Kit specifically removes 20 ... plasma or serum in preparation for further ... into the plasma proteome whether you use ... chromatography or go straight to mass spectrometry. ...
... Since OligoEngine introduced the industry's first ... have constantly strived to keep these tools ... research reports in the field of RNAi. ... enhanced, and expanded RNAi design tools, OligoEngine ...
... for enzyme-/substrate-based blotting what intensifying screens do for ... to 10-fold (or one order of magnitude) in ... Enhancer membrane treatment is a simple, 15-minute procedure ... Western blotting protocol. The result is an increase ...
Biology Products: